early stage NSCLC (stages I-III)

Question 1

What is the role of EGFR in patients with unresectable stage III NSCLC?

Describe the patient population, study arms, primary endpoint and results of the LAURA trial?

Answer 1

LAURA
Stage III NSCLC, EGFR mutated (exon 19 del, L858R) undergoing definitive chemoRT
2:1 Osimertinib versus Placebo until disease progression
primary endpoint: Progression free survival
39.1 months versus 5.6 months (HR 0.16)

radiation pneumonitis in 48% of patients on osimertinib (38% in placebo)

Lu Shun, NEJM 2024 PMID 2402614